113294-82-9

113294-82-9 structure

Name: angiopeptin
Chemical Name: 3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-norvalyl-L-cysteinyl-L-threoninamide
CAS Number: 113294-82-9
Molecular Formula: C₅₄H₇₁N₁₁O₁₀S₂
Molecular Weight: 1098.339
Catalog: Signaling Pathways GPCR/G Protein Somatostatin Receptor
Create Date: 2021-09-11 18:53:41
Modify Date: 2024-01-10 16:48:40
Angiopeptin, a cyclic octapeptide analogue of somatostatin, markedly inhibits myointimal proliferation in response to endothelial cell injury. Angiopeptin is a potent and full agonists to inhibit adenylate cyclase or stimulate extracellular acidification through the sst2 or sst5 receptor. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 production[1][2].

Name	3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-norvalyl-L-cysteinyl-L-threoninamide
Synonyms	L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-norvalyl-L-cysteinyl- 3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-norvalyl-L-cysteinyl-L-threoninamide

Description	Angiopeptin, a cyclic octapeptide analogue of somatostatin, markedly inhibits myointimal proliferation in response to endothelial cell injury. Angiopeptin is a potent and full agonists to inhibit adenylate cyclase or stimulate extracellular acidification through the sst2 or sst5 receptor. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 production[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Somatostatin Receptor
In Vivo	Angiopeptin (20 and 50μg/kg; i.h.) significantly inhibits neointimal formation[1]. Angiopeptin (20 μg/kg; per day) significantly inhibits coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%[1]. Animal Model: Rat (model of myointimal proliferation)[1] Dosage: 20 and 50 μg/kg Administration: I.h. Result: Inhibited neointimal formation. Animal Model: New Zealand white rabbit (model of myointimal proliferation)[1] Dosage: 20 μg/kg Administration: Per day Result: Inhibited coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%.
References	[1]. Lundergan CF, et al. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol. 1991;17(6 Suppl B):132B-136B. [2]. Alderton F, et al. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol. 2001;132(3):760-766.